logo

For the Inventor, By the Inventor

New York, NY, United States of America

Ludwig Institute for Cancer Research Limited


USPTO Granted Patents = 525



Trademarks = 5

Forward Citations = 4,298

Loading Chart...
Loading Chart...

765 inventors (with patents filed for the assignee):

goldMedal Thierry R Boon-Falleur (131 out of 143 patents)

silverMedal Pierre Van Der Bruggen (66 out of 73 patents)

bronzeMedal Lloyd J Old (56 out of 122 patents)

4.  Gerd J Ritter (51 out of 58 patents)

5.  Pierre G Coulie (46 out of 53 patents)

6.  Benoit Van Den Eynde (30 out of 30 patents)

7.  Michael Pfreundschuh (29 out of 31 patents)

8.  Carl-Henrik Heldin (28 out of 40 patents)

9.  Yao-tseng Chen (28 out of 42 patents)

10.  Taha Merghoub (26 out of 42 patents)

11.  David Schaer (26 out of 26 patents)

12.  Ulf Eriksson (26 out of 43 patents)

13.  Marc A Van Dijk (26 out of 42 patents)

14.  Michael Derek Waterfield (26 out of 31 patents)

15.  Jacques Van Snick (25 out of 25 patents)


Core Competencies:
Whole Genome Methylation Analysis
Anti-CTLA-4 Antibodies
TGF-β3 Specific Antibodies
Viral Vectors
Cytosine Modifications
Kinase Mutants
Small-RNA Transcriptome Sequencing
Immune Cell Receptor Sequencing
Nuclease Modulators
Extrachromosomal DNA
iNKT Cell Modulators
PLK4 Inhibitors

525 patents:

1. 12410467 - Bisulfite-free, whole genome methylation analysis (2025-09-09),
2. 12297276 - Anti-TEM1 antibodies and antigen-binding portions thereof (2025-05-13),
3. 12246066 - Anti-CTLA-4 antibodies and methods of use thereof (2025-03-11),
4. 12221477 - TGF-β3 specific antibodies and methods and uses thereof (2025-02-11),
5. 12195556 - Reversible protein multimers, methods for their production and use (2025-01-14),
6. 12180501 - Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer (2024-12-31),
7. 12173370 - Whole-genome haplotype reconstruction (2024-12-24),
8. 12071660 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-08-27),
9. 11993653 - Antibodies and methods of use thereof (2024-05-28),
10. 11987843 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-05-21),
11. 11959136 - Bisulfite-free, base-resolution identification of cytosine modifications (2024-04-16),
12. 11957751 - TGF-β1 specific antibodies and methods and uses thereof (2024-04-16),
13. 11946043 - Selective labeling of 5-methylcytosine in circulating cell-free DNA (2024-04-02),
14. 11897962 - Anti-GITR antibodies and methods of use thereof (2024-02-13),
15. 11833168 - Compounds and methods for increasing STMN2 expression (2023-12-05),
Ludwig Institute for Cancer Research (LICR) is a nonprofit organization dedicated to advancing the understanding and treatment of cancer. With a global network of researchers and laboratories, LICR conducts cutting-edge research focused on improving patient outcomes and developing innovative cancer therapies. Through collaboration and scientific excellence, LICR strives to make significant contributions to the field of cancer research and ultimately help patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
525 Patents

#31 in New York, NY

#57 in New York

#903 in US

#1,805 in the World

...
New York, NY, United States of America

Ludwig Institute for Cancer Research Limited

Forward Citations = 4,298

765 inventors:

goldMedal Thierry R Boon-Falleur (131 out of 143 patents)

silverMedal Pierre Van Der Bruggen (66 out of 73 patents)

bronzeMedal Lloyd J Old (56 out of 122 patents)

4.  Gerd J Ritter (51 out of 58 patents)

5.  Pierre G Coulie (46 out of 53 patents)

Please report any incorrect information to support@idiyas.com
Loading…